Ulcerative Colitis
Red Flags — act before continuing history
| Red flag | Why dangerous | Action |
|---|---|---|
| Severe UC: ≥6 bloody stools/day + ANY systemic feature | Truelove-Witts severe UC criteria: stool frequency ≥6/day with blood + fever >37.8°C, HR >90, Hb <105, or ESR >30. Requires IV corticosteroids, IV fluids, nutritional support, and colectomy risk assessment. Mortality if not treated promptly. | Same-day hospital admission |
| Toxic megacolon (colonic dilatation >6cm) | Transverse colon dilatation >6cm on plain X-ray with systemic toxicity (fever, tachycardia, abdominal distension). Perforation risk is high — mortality 20–30% without urgent surgical intervention. Do not perform colonoscopy. | 999 — surgical emergency |
| Signs of peritonism or perforation | Sudden severe abdominal pain with peritoneal signs (guarding, rebound, rigidity) in a UC patient indicates perforation until proven otherwise. This is a life-threatening surgical emergency requiring immediate hospital transfer. | 999 immediately |
| New or changing abdominal mass in longstanding UC | A palpable abdominal mass in a patient with longstanding UC requires urgent investigation for CRC. UC is a pre-malignant condition; cancer risk increases with disease duration and extent. | 2WW CRC referral |
| Acute uveitis (red eye, photophobia, visual change) | Anterior uveitis is an extraintestinal manifestation of UC that can cause permanent vision loss if untreated. Requires same-day ophthalmology review — not topical OTC treatments alone. | Same-day ophthalmology |
| Significant haematochezia causing haemodynamic instability | Massive colonic haemorrhage in UC can cause haemodynamic compromise. Signs: pallor, hypotension, tachycardia, dizziness on standing. Requires immediate hospital transfer. | 999 immediately |
| C. difficile colitis suspected (recent antibiotics + diarrhoea) | C. difficile superinfection in UC patients on immunosuppressants is associated with high morbidity and mortality. Cannot be distinguished clinically from a UC flare — stool cultures mandatory before any immunosuppression. | Stool culture urgently; do not start steroids |
Safeguarding Considerations — Consider in Every Consultation
🏠 Domestic Abuse / Relationship Stress
- UC’s impact on intimacy, urgency, and self-image can cause significant relationship strain and vulnerability to abuse
- Partners who are unsupportive of IBD management (dismissing symptoms, undermining treatment) can impair disease control and mental health
- Screen sensitively if patient presents repeatedly with poorly controlled UC despite apparently adequate treatment — home environment may be contributing
- Use SAFE questions if domestic abuse is suspected; document findings and refer per safeguarding protocol
👴 Children and Young People with UC
- UC in children and adolescents can cause faltering growth, delayed puberty, and significant school absence; refer to paediatric gastroenterology
- Young people with UC may underreport symptoms due to embarrassment about bowel function, leading to delayed treatment escalation
- School arrangements (toilet access, exam accommodations) require a GP letter and, where severe, a care plan
- Mental health impact in adolescents with UC is significant — body image, social exclusion, and peer relationships are all affected
🧠 Mental Health and Self-Neglect
- Depression and anxiety occur in 25–35% of UC patients and worsen disease outcomes through HPA axis activation and non-adherence
- Self-neglect (stopping medications, missing review appointments) in a patient with UC may reflect a mental health crisis rather than non-compliance
- Non-adherence to 5-ASA is the single most common cause of UC relapse — always explore the reason non-judgmentally before escalating treatment
- Offer PHQ-9 and GAD-7 at every annual review; psychological therapy referral significantly improves UC outcomes
💊 Immunosuppression Safety
- Azathioprine, biologics, and steroids cause significant immunosuppression; infection risk is substantially increased
- Patients on immunosuppressants must be advised about infection risk and instructed to seek urgent assessment for fever or signs of sepsis
- Varicella (chickenpox) exposure in an immunosuppressed UC patient requires urgent VZIG (within 10 days); document vaccination status before starting immunosuppressants
- Live vaccines are contraindicated in immunosuppressed patients — check vaccination status before starting azathioprine or biologic therapy
🏢 Work and Career Impact
UC urgency and unpredictable flares cause significant occupational impairment. Patients may limit career choices, avoid promotion, or reduce hours during active disease. Access to toilets at work is legally protected under the Equality Act 2010 for UC patients.
“Has this been affecting your work? Do you have reliable toilet access? I can write a supporting letter for your employer if that would help.”Fit note and employer letter; occupational health referral; Equality Act 2010 — UC is a disability under UK law
🧠 Anxiety and Depression
25–35% of UC patients have comorbid anxiety or depression. The unpredictable nature of UC (not knowing when the next flare will happen) creates chronic anticipatory anxiety. Depression is associated with worse disease outcomes, higher hospitalisation rates, and non-adherence.
“Living with a condition like this that comes and goes unpredictably can take a real toll on your mood. How are you feeling in yourself?”PHQ-9 and GAD-7 at every annual review; psychological therapy referral; antidepressants as appropriate (avoid NSAIDs)
👥 Relationships and Intimacy
UC affects intimate relationships through urgency, abdominal pain, body image concerns, and treatment side effects. Disclosure to partners, embarrassment about symptoms, and reduced sexual function during flares are common but rarely discussed in clinical consultations.
“Has the condition been affecting your personal relationships? I ask because this is something many people with UC find difficult to talk about, but it is important.”Validate the impact without probing intrusively; refer to IBD nurse specialist for psychosexual support discussions
💐 Family Planning and Pregnancy
UC and its treatments have complex implications for fertility and pregnancy. Methotrexate is absolutely contraindicated in pregnancy and for 6 months before conception in both men and women. Many patients with UC voluntarily reduce family size due to disease-related concerns that are often based on inaccurate information.
“Are you thinking about starting or expanding your family? The timing and the medications you are on are important considerations — I want to make sure we plan that carefully.”Mesalazine and azathioprine: generally safe in pregnancy under specialist guidance; methotrexate: absolutely contraindicated
🏋 Diet, Exercise, and Lifestyle
Many UC patients develop extreme dietary restriction, cutting entire food groups based on perceived triggers without evidence. Contrary to IBS, there is no strong evidence for specific dietary modifications in UC remission. Dietary restriction can cause malnutrition without improving disease.
“Have you been restricting your diet? I want to make sure you are eating enough — particularly during a flare, when nutrition is really important for recovery.”Dietitian referral for nutritional assessment; no evidence for specific exclusion diets in UC; adequate protein and caloric intake essential
🚪 Fear of Colectomy and Cancer
Fear of colectomy and fear of cancer are the dominant long-term fears in UC. These fears drive both over-medicating (requesting biologics pre-emptively) and under-seeking (avoiding surveillance colonoscopy out of fear of bad news). Both fears must be addressed with accurate, evidence-based data at the GP level.
“Are you worried about the long-term picture — particularly about the cancer risk or the chance of needing an operation? I can give you some specific numbers that may help.”Cancer risk is real but manageable with surveillance; colectomy rates are declining with biologics; address both fears with specific evidence, not vague reassurance
- Not applying Truelove-Witts criteria to assess flare severity before deciding on management
- Starting steroids before excluding infective colitis with stool cultures
- Not asking about extraintestinal manifestations (particularly eye symptoms)
- Missing nocturnal symptoms as a severity indicator
- Failing to check cancer surveillance status and last colonoscopy date
- Not exploring medication adherence before escalating treatment
Same-Day Hospital Admission
Admit today- Severe UC: ≥6 bloody stools/day + systemic featureFever >37.8°C, HR >90 bpm, Hb <105 g/L, or ESR >30 — requires IV hydrocortisone 100mg QDS; do not manage in primary care
- Toxic megacolon (colonic dilatation >6cm on X-ray)Systemic toxicity + abdominal distension → 999 immediately; surgical emergency; do NOT colonoscope
- Peritonism or suspected perforationSudden severe pain + peritoneal signs → 999; IV access + fluid resuscitation en route
- Haemodynamic compromise from GI bleedingTachycardia, hypotension, pallor → 999; IV access; group and save; fluid resuscitation
- Acute uveitis with visual changeSame-day ophthalmology — not GP topical treatment; risk of permanent vision loss within hours
Urgent GI Review / Escalation
Days to 2 weeks- Moderate UC flare: 4–6 stools/day with bloodContact IBD nurse specialist same day; consider oral prednisolone 40mg OD; urgent GI review within 1–2 weeks
- First presentation of probable UC (bloody diarrhoea >2 weeks)Stool cultures; urgent GI referral for colonoscopy and biopsy; do not diagnose UC without histology
- Steroid-refractory or steroid-dependent flarePatient requiring >2 steroid courses per year or unable to taper → urgent IBD review for immunomodulator or biologic
- New extraintestinal manifestationNew joint disease, skin lesion, or eye symptoms → relevant specialist review and IBD co-management within 1 week
- Surveillance colonoscopy overdue (>1 year past due date)Arrange urgently through gastroenterology; document in referral letter
- Suspected C. difficile in UC patient on immunosuppressantsStool C. difficile toxin same day; urgent GI advice; do not start or continue steroids until excluded
Primary Care Management
GP practice- Mild UC flare: <4 stools/day, minimal systemic features, well patientOptimise 5-ASA dose; add topical mesalazine enema/suppository; review in 4 weeks
- Known UC in remission — annual reviewCheck adherence; arrange surveillance colonoscopy if due; monitor bloods; vaccination update
- Azathioprine monitoring (stable patient)FBC and LFTs 3-monthly; TPMT confirmed; IBD nurse review annually
- Calcium and vitamin D supplementation for steroid-treated patientsRoutine prescribing alongside steroid courses; document steroid exposure history for DEXA decision
- Vaccination update in immunosuppressed UC patientFlu, pneumococcal, COVID-19, HBV, HPV as per Green Book; live vaccines contraindicated on immunosuppressants
- Prescribing steroids for a presumed flare without first ordering stool cultures to exclude infective colitis
- Managing severe UC in primary care rather than arranging hospital admission
- Missing the Truelove-Witts criteria for severity assessment — using clinical impression alone
- Not contacting the IBD nurse specialist for a moderate flare before next steps
- Not checking pulse and temperature as part of severity assessment in a flare
- Missing uveitis by not examining eyes in a UC patient with a red eye
- Not performing postural BP check in a patient with high-volume diarrhoea
- Missing pyoderma gangrenosum — attempting wound debridement (pathergy risk)
- Starting steroids without ordering stool cultures and C. difficile toxin first
- Starting azathioprine without TPMT enzyme testing
- Not checking Truelove-Witts blood criteria (FBC, ESR) to confirm severity
- Arranging colonoscopy as an emergency investigation in severe UC (contraindicated — perforation risk)
“What you have is called ulcerative colitis — UC for short. It is a condition where the immune system attacks the lining of the large bowel, causing inflammation, ulcers, and bleeding. Unlike Crohn’s disease, which can affect any part of the gut, UC always starts in the rectum — the very end of the bowel — and can spread upwards. It is a long-term condition that tends to come and go — you will have flares when symptoms are active, and then periods of remission where you feel completely normal. It is not caused by anything you ate or did, and it is not contagious. The good news is that most people with UC lead completely normal lives with the right treatment. The key is to get the inflammation under control and then keep it under control with maintenance medication.”
“I thought I just had IBS — can IBS cause bleeding?”
“IBS is a completely different condition to UC — IBS does not cause bleeding, and it does not cause the kind of inflammation we are seeing. The blood in your stools tells us there is active inflammation in the bowel, which is what we need to investigate and treat. IBS is a diagnosis we can make if everything else comes back normal, but bleeding means we need to be sure.”
“Is this going to turn into cancer? My father had bowel cancer.”
“This is one of the most important things I want to address. Yes, there is a higher risk of bowel cancer with UC — particularly if you have had the condition for a long time and it affects a large part of the bowel. But with the right treatment and regular surveillance colonoscopies, this risk is very much reduced to close to the general population risk. We will set up a surveillance programme specifically for you.”
Ulcerative Colitis (UC)
Continuous mucosal inflammation from rectum, extending proximally. Histology: crypt distortion, goblet cell depletion, basal plasmacytosis. Classified by Montreal extent: E1 proctitis, E2 left-sided, E3 extensive.
Proctitis (E1)
Inflammation confined to the rectum (<15cm from anus). Managed primarily with topical therapy (suppositories). Associated with tenesmus and urgency disproportionate to stool frequency.
Crohn’s Disease
Transmural, skip lesions, can affect any part of the GI tract, perianal involvement, granulomas on histology. Can mimic UC in the colon (Crohn’s colitis). Treatment differs significantly (methotrexate is used; 5-ASA evidence less strong).
Infective Colitis
Campylobacter, Salmonella, Shigella, CMV, C. difficile, amoeba. Acute onset, travel history, recent antibiotics. Stool cultures distinguish; never start steroids before exclusion.
Microscopic Colitis
Normal endoscopy but abnormal histology; watery non-bloody diarrhoea; predominantly middle-aged women; NSAIDs, PPIs, and SSRIs associated; managed with budesonide.
Ischaemic Colitis
Older patients with vascular risk factors; sudden onset, left-sided abdominal pain; watershed area of splenic flexure most affected; requires CT angiography.
Toxic Megacolon
Colonic dilatation >6cm with systemic toxicity; most feared acute complication; perforation risk; requires immediate surgical assessment and IV corticosteroids. Do NOT attempt colonoscopy.
Colorectal Cancer in UC
Risk: E3 pancolitis >10 years; cumulative 5–8× general population risk; dramatically reduced with surveillance colonoscopy and 5-ASA chemoprevention. 2WW referral if suspected.
Fulminant Colitis / Perforation
Peritoneal signs + systemically unwell; perforation can occur without preceding toxic megacolon; 999; IV antibiotics + surgical assessment; emergency colectomy may be required.
- Diagnosing UC without histological confirmation — the diagnosis requires endoscopy + biopsy
- Failing to address the cancer risk question directly and with accurate data
- Not distinguishing UC from Crohn’s disease when both are in the differential
- Not explaining the relapsing-remitting nature of UC and what this means for the patient’s future
- Prescribing steroids without C. difficile exclusion — regardless of how certain you are about the diagnosis
- Debridement of a skin lesion that may be pyoderma gangrenosum (causes pathergy)
- Not contacting the IBD nurse specialist as first point of contact for a moderate flare
- Treating suspected uveitis with OTC conjunctivitis eye drops
Validate — the desire to manage naturally or stop medication
Many patients with UC want to manage the condition with diet alone or want to stop maintenance medications when they feel well. Both are understandable responses, but both lead to higher relapse rates and disease progression. Acknowledging the desire before explaining the evidence maintains the therapeutic relationship.
“I completely understand why you would want to manage this without long-term medication — nobody wants to take tablets indefinitely. Let me explain why the medicine is important even when you feel well.”Explain — why maintenance therapy matters even in remission
5-ASA (mesalazine) reduces the risk of relapse by 40–50% and has a documented chemoprevention effect against CRC in UC. Stopping maintenance therapy significantly increases the relapse rate and CRC risk. The medication needs to be taken continuously, not just during flares.
“The mesalazine is not just treating your symptoms — it is actively protecting the bowel lining and reducing the long-term cancer risk. Even when you feel completely well, the microscopic inflammation can still be there. That is why it needs to be taken every day, indefinitely.”Negotiate — acknowledge lifestyle changes that genuinely help
While no specific diet treats UC, there is good evidence for not smoking, reducing stress, and maintaining good nutrition. Acknowledging these genuine lifestyle contributions respects the patient’s agency and improves engagement with the treatment plan.
“The lifestyle changes you are making — managing stress, not smoking, eating well — do genuinely help. But they work alongside the medication, not instead of it. Let’s agree on a plan that combines both.”Nicotine has a protective mucosal effect in UC — smokers have lower UC incidence. However, smoking cessation is one of the most common triggers for a UC flare (the “paradox of cessation”). Stopping smoking is still strongly recommended for overall health.
Strongly recommend smoking cessation for cardiovascular and cancer risk. However, warn the patient and gastroenterology team that stopping smoking may trigger a UC flare. Gastroenterology should be made aware so the treatment plan can be adjusted proactively.
Psychological stress activates the HPA axis, increases intestinal permeability, and alters gut microbiome composition. Stress is a recognised trigger for UC flares through neuroimmunological mechanisms.
Mindfulness-based stress reduction (MBSR), gut-directed CBT, and relaxation therapy all have evidence in IBD. NHS Talking Therapies referral for anxiety or depression. Peer support groups (Crohn’s & Colitis UK). IBD nurse can facilitate access to psychological support.
No specific diet has proven benefit for inducing or maintaining remission in UC (unlike enteral nutrition in Crohn’s). However, nutritional deficiency during flares impairs recovery and increases surgical risk. Adequate protein intake and caloric density are priorities.
Dietary restrictions should not be imposed unless specific foods are causing symptoms. Dietitian referral for patients with significant weight loss, nutritional deficiencies, or malnutrition during flares. Iron supplementation for anaemia. Vitamin D supplementation for all patients on steroids.
Regular moderate exercise reduces inflammatory cytokine levels, improves mental health, and reduces fatigue in IBD. Exercise-related gut symptoms may be increased during active disease but are manageable with timing of exercise relative to meals and bathroom access.
Encourage regular moderate exercise in remission. During active flares, rest as needed but aim to resume activity as symptoms allow. Yoga and swimming are well-tolerated. RADAR key for accessible toilet access during outdoor activities.
Immunosuppressants (azathioprine, biologics) significantly increase infection risk. Pre-treatment vaccination is essential. Live vaccines are absolutely contraindicated in immunosuppressed patients — they can cause vaccine-strain disease.
Annual influenza (inactivated), COVID-19 boosters, pneumococcal (PCV13 + PPV23), hepatitis B series (check serology first), VZV serology (give varicella vaccine before immunosuppression if non-immune), HPV per JCVI schedule, meningococcal ACWY. All live vaccines must be given at least 4 weeks before starting immunosuppressants.
NSAIDs inhibit cyclooxygenase enzymes, reducing mucosal prostaglandin production. This impairs the gut’s protective mucosal layer and triggers inflammation in patients with UC. Up to 20% of UC flares are associated with NSAID use.
All NSAIDs should be avoided in active UC. Paracetamol is safe for analgesia. For patients on anticoagulation with concurrent pain, specialist advice may be needed. Document NSAID avoidance advice in the notes and on the summary care record.
- E1 proctitis: Mesalazine suppository 1g OD (topical) alone is first-line; add oral if response inadequate
- E2 left-sided: Oral mesalazine 2.4g/day + mesalazine enema 1–4g OD (combined superior to either alone)
- E3 extensive: Oral mesalazine 4.8g/day (maximum dose) + topical; high-dose oral is superior to standard dose for induction
- Maintenance: Continue indefinitely at the dose that achieved remission; 5-ASA is both treatment AND CRC chemoprevention
- Sustained-release preparations (Pentasa, Mezavant) may be better tolerated and offer once-daily dosing, improving adherence
- Oral prednisolone 40mg OD: For moderate-to-severe flare; taper by 5mg/week from week 2 over 8 weeks total
- Topical budesonide (Budenofalk enema): For left-sided flare; less systemic absorption than prednisolone; useful if systemic steroid side effects are a concern
- IV hydrocortisone 100mg QDS: Severe UC in hospital only; switch to oral prednisolone 40mg when tolerating oral intake
- Calcium + vitamin D: Always prescribe alongside steroids (DEXA if >3 months cumulative steroid exposure)
- 🔴 Steroids are never appropriate maintenance therapy — if required more than 2 courses/year or unable to taper, escalate to immunomodulator
- Azathioprine 2–2.5mg/kg/day: First-line immunomodulator for steroid-dependent or steroid-refractory UC; TPMT testing mandatory before initiating; takes 3–6 months for full effect
- 6-Mercaptopurine (6-MP): Alternative to azathioprine for those who cannot tolerate it (nausea, hepatitis); NOT for azathioprine-induced pancreatitis
- Monitoring: FBC and LFTs monthly for 3 months, then 3-monthly; sun protection (increased skin cancer risk)
- Biologics (infliximab, vedolizumab, ustekinumab): For immunomodulator failure or severe refractory disease; specialist-initiated only; GP monitors for infections and attends shared care agreements
- Colectomy is curative for UC (unlike Crohn’s); used in medically refractory severe UC, complications (perforation, cancer), or patient preference
- Proctocolectomy with ileo-anal pouch anastomosis (IPAA) is the preferred restorative procedure; allows continence and avoids permanent stoma in most patients
- Post-colectomy complications: pouchitis (treat with metronidazole or ciprofloxacin), cuffitis (topical mesalazine); refer to IBD team
- GP role: support during surgical decision-making; refer to IBD nurse; address psychosocial impact of surgery and stoma potential
- Low risk (E1 proctitis, E2 <8 years, no other risk factors): colonoscopy every 5 years
- Intermediate risk (E2–E3, 8–20 years, mild active inflammation, previous dysplasia >5 years ago): every 3 years
- High risk (pancolitis >20 years, previous dysplasia in last 5 years, PSC, FH CRC <50): annual colonoscopy with chromoendoscopy
- GP role: ensure surveillance is arranged; document last colonoscopy date; refer urgently if overdue high-risk patient
Select clinical scenario for drug guidance
Moderate flare: Contact IBD nurse; stool cultures; prednisolone 40mg OD (after C. diff excluded)
Severe flare: Same-day hospital admission; IV hydrocortisone; do NOT manage in primary care
Maintenance: Mesalazine (dose + formulation per extent) lifelong; never stop in remission
Steroid-dependent: Urgent GI referral; azathioprine (after TPMT); biologic if immunomodulator fails
“Mesalazine is the cornerstone of your treatment — it reduces inflammation, prevents flares, and importantly, it protects against the increased cancer risk that comes with UC over time. It needs to be taken every day, even when you feel completely well. Think of it as a shield, not a fire extinguisher.”
SCA pearl: Non-adherence to mesalazine is the most common reason for UC flares — always explore adherence before escalating treatment. The chemoprevention argument (reduced CRC risk) is the most powerful motivator for adherent patients who are reluctant to take long-term medication. Naming this specifically scores in the Tasks domain.
“These steroids will help get this flare under control quickly. They are not a long-term treatment — we will reduce them gradually over 8 weeks. They can affect your sleep and appetite, and you might feel a bit more energetic than usual. Take them in the morning with breakfast. Do not stop them suddenly.”
SCA pearl: The two most commonly scored errors in UC prescribing examinations are: (1) starting steroids without stool cultures (C. difficile exclusion) and (2) prescribing steroids as maintenance rather than only for acute flares. Both are patient safety issues and both are explicitly scored. Articulating the taper schedule (5mg/week from week 2) demonstrates clinical depth.
“This medication reduces the activity of your immune system to prevent further flares. It takes 3–6 months to reach its full effect. During this time, you will need regular blood tests to make sure it is not affecting your blood count or liver. If you develop a fever, come back urgently — your immune system is less able to fight infections while you are on this medication.”
SCA pearl: Three things score in the SCA for azathioprine: (1) TPMT testing before starting; (2) explicit drug interaction warning with allopurinol; (3) blood monitoring schedule (FBC + LFTs). Mentioning the 3–6 month delay to therapeutic effect manages patient expectations about flare prevention. Never initiate without specialist confirmation — say so clearly.
“This is a powerful medication that specifically targets the part of the immune system causing inflammation in your bowel. It is given by injection or infusion at the hospital. You will need regular blood tests and checks. The main risk is infection — please come to us urgently if you develop a fever or feel unwell.”
SCA pearl: The GP’s role with biologics is monitoring and recognising complications, not initiating. Demonstrating awareness of TB and hepatitis B screening, live vaccine contraindication, and the shared care model scores in the Tasks domain. Never offer to initiate a biologic without specialist input — this is an examiner red flag.
Work and Legal Rights
UC is a disability under the Equality Act 2010. Employers must make reasonable adjustments including unrestricted toilet access, flexible start times during flares, and time off for appointments. Patients are protected from dismissal due to UC if these rights are documented.
GP letter to employer supporting reasonable adjustments; fit note during flares; occupational health referral; document disability status in medical records.
“You have legal rights as someone with UC. I can write a letter to your employer explaining what adjustments they should make — including unrestricted toilet access. This is protected under the Equality Act.”Travel and Urgent Access to Toilets
UC urgency makes travel, commuting, and social activities stressful. Fear of not reaching a toilet in time significantly restricts daily life. The RADAR key scheme provides access to over 10,000 locked accessible public toilets in the UK. Crohn’s & Colitis UK provides a “Not every disability is visible” card for urgent situations.
Register for RADAR key; Crohn’s & Colitis UK membership; “Can’t Wait Card” for urgent toilet access.
“I want to tell you about the RADAR key scheme — it gives you access to accessible toilets across the UK. And Crohn’s & Colitis UK have cards that explain your need for urgent toilet access without embarrassment.”Mental Health and Chronic Illness Burden
25–35% of UC patients have clinically significant anxiety or depression. Fear of flares, cancer, and colectomy creates chronic anticipatory anxiety. Depression is associated with non-adherence, hospitalisation, and surgical rates.
PHQ-9 and GAD-7 at every annual review; NHS Talking Therapies referral; IBD nurse psychosocial support; Crohn’s & Colitis UK peer support groups; formal psychological therapy.
“Living with a relapsing condition that comes and goes without warning takes a real toll. How is your mood? I want to make sure we are supporting your mental health as well as your bowel.”Family Planning and Fertility
Active UC during pregnancy increases risk of preterm birth and low birthweight. Mesalazine is safe in pregnancy. Methotrexate is absolutely contraindicated. Some biologics can be used in pregnancy under specialist guidance. Men on azathioprine should use contraception for 6 months after stopping.
Pre-conception counselling with gastroenterology; ensure disease is in remission before conception; medication review; obstetric co-management; folic acid 5mg OD.
“If you are thinking about starting a family, I want to make sure we plan this carefully with your gastroenterology team — some medications need to be reviewed and it is better to conceive in remission.”Fear of Colectomy and Surgery
Colectomy is curative for UC and rates are declining with biologics, but it remains a feared outcome. Many patients make significant life decisions (career choices, family size, relationship decisions) based on an overestimated likelihood of colectomy. Accurate information reduces fear.
Realistic information about surgical rates (approximately 20–30% lifetime risk with good medical management); colostomy is not inevitable — ileo-anal pouch preserves continence in most cases; stoma nurse referral if indicated.
“I hear that the possibility of surgery is something that frightens you. Can I give you some specific information? Most people with UC never need an operation, and for those who do, there are excellent surgical options that allow continence.”Cancer Surveillance Adherence
Cancer fear both drives and paradoxically prevents surveillance adherence. Some patients miss surveillance colonoscopies because they are afraid of a bad result. This avoidance significantly increases cancer risk by allowing dysplasia to go undetected.
Frame surveillance as empowering rather than alarming: “This colonoscopy is how we catch any changes early, when they are completely treatable.” Document surveillance due dates prominently in the record.
“I know the colonoscopy is something you have been putting off. I understand why — it can feel like you are looking for bad news. But the purpose is actually the opposite: it is how we find any small changes early enough to treat them easily.”2–4 weeks — Acute flare review
Review response to prednisolone; check stool frequency and blood; confirm stool culture results; assess steroid side effects; if no response at 2 weeks, contact IBD team urgently — do not extend steroid course without specialist input. Ensure calcium + vitamin D is prescribed alongside steroids.
3 months — Remission check and monitoring
Confirm remission (stool frequency, blood, abdominal pain, energy levels). Check azathioprine blood monitoring if initiated. Calprotectin to confirm mucosal response. Review adherence to mesalazine. Update vaccination records. Document extraintestinal manifestation status.
6 months — Stability review and GI follow-up
FBC, CRP, calprotectin, U&E, LFTs, albumin. Azathioprine monitoring (3-monthly). Confirm gastroenterology outpatient appointment has been attended. PHQ-9/GAD-7 for mental health screen. Cancer surveillance due date confirmed.
Annual review — GP-led IBD review
FBC, CRP, LFTs, U&E, vitamin D, ferritin, folate, B12. Azathioprine monitoring continued. Cancer surveillance colonoscopy date confirmed and arranged. Steroid exposure tallied (DEXA if >3 months cumulative). PHQ-9/GAD-7. Vaccination update. NSAID avoidance confirmed. Crohn’s & Colitis UK membership offered.
Open access — any new or worsening symptoms
Contact IBD nurse first for flares in established patients. Contact practice urgently for: eye symptoms (uveitis), significant PR bleeding, abdominal mass, fever >38°C, symptoms meeting Truelove-Witts severe criteria. Same-day access for suspected severe UC.
UC monitoring memory rule
Every UC review: FBC (anaemia, myelosuppression) · CRP/calprotectin (disease activity) · U&E + creatinine (mesalazine nephrotoxicity) · LFTs + albumin (azathioprine hepatotoxicity; nutritional status) · Surveillance scope date (cancer prevention) · Steroid exposure tally (osteoporosis prevention — DEXA if >3 months) · Vaccination status (immunosuppression) · Mental health (PHQ-9/GAD-7 annually) · NSAID avoidance (flare prevention) · Adherence (non-adherence = most common cause of relapse).
⚠ Three scenario-specific phrases — use these verbatim
Why safety-netting matters beyond clinical care
- Prescribing steroids without stool cultures explicitly stated at close of consultation
- Not summarising the agreed plan before ending the consultation
- Missing the cancer surveillance conversation entirely
- Failing to address the 5-ASA adherence message in a known UC patient
- No closing question for remaining concerns
- Truelove-Witts severity criteria applied and documented
- Stool cultures before steroids — explicitly stated
- 5-ASA adherence addressed and importance of maintenance communicated
- Cancer surveillance status checked and next scope arranged or noted
- Azathioprine monitoring (TPMT + FBC + LFTs) discussed if relevant
- ICE fully explored including cancer fear and colectomy fear
- Desire to manage with diet alone validated before evidence shared
- Management plan negotiated; patient’s preferences incorporated
- Psychosocial impact addressed (work, legal rights, mental health)
- Closing question asked; remaining concerns addressed
- IBD nurse role explained as key point of contact for flares
Who you are
Marcus, 32-year-old software engineer. Diagnosed with UC (E2 left-sided) 4 years ago. Has been on mesalazine 2.4g/day but admits he has been taking it “most days” rather than every day because he feels well between flares. The current flare started 3 weeks ago and has progressively worsened. He has been opening his bowels 7–8 times a day with significant fresh blood. He has a low-grade fever (37.9°C) and his heart rate is 98 bpm. He has lost 3 kg. He had his last colonoscopy 3 years ago.
Hidden agenda and ICE
Terrified of bowel cancer — his uncle died of it and he has noticed the blood is getting worse. He wants to know if this is cancer. He also secretly wants to stop the mesalazine because he read that long-term 5-ASA use causes kidney problems. He is reluctant to go to hospital because he has an important work project. He thinks the flare is related to stress from work.
Symptoms if asked directly
- Stool frequency: 7–8/day with significant fresh blood
- Nocturnal symptoms: yes, waking 2–3 times per night to open bowels
- Fever: yes, feels hot; temperature 37.9°C measured at home
- Heart rate: 98 bpm (tell if asked or measured)
- Weight loss: 3 kg over 3 weeks without trying
- Abdominal pain: lower left abdominal cramping, constant background
- No perianal symptoms; no joint pain; no eye symptoms
- Last colonoscopy: 3 years ago; no surveillance appointment received
Bonus details and resolution
- Mesalazine adherence: approximately 60–70% — discloses if asked non-judgmentally
- NSAIDs: took ibuprofen for 2 weeks for back pain starting 4 weeks ago (important trigger)
- Work impact: has missed 5 days in the past 3 weeks; job at risk
- Resolution: accept hospital admission if clinician explains clearly why home management is unsafe; initially resistant but yields to clinical evidence
- Challenge phrase: “Can I not just take some steroids at home? I really cannot afford to take time off work right now”
Resolution: Accept hospital admission if the clinician explains: (1) the Truelove-Witts criteria (6+ bloody stools + fever + HR >90 = severe UC requiring IV treatment); (2) the risk of toxic megacolon if managed at home; (3) that home oral steroids are not the appropriate treatment for this level of severity. Remain resistant to the examination unless the clinical reasoning is clearly explained. If the clinician identifies the ibuprofen as a trigger and addresses it, award an additional Relating to Others mark. Cancer fear must be specifically addressed — do not accept generic reassurance.
- ≥6 bloody stools/day + ANY of:
- Fever >37.8°C
- HR >90 bpm
- Hb <105 g/L
- ESR >30 mm/hr
- 4–6 stools/day with blood
- Mild systemic features
- Stool cultures + C. diff first
- Contact IBD nurse same day
- Prednisolone 40mg OD if infection excluded
- <4 stools/day ± blood
- No systemic features, well patient
- Optimise 5-ASA dose
- Add topical enema/suppository
- Review adherence first
🔴 NEVER use steroids as maintenance therapy
🔴 NEVER start azathioprine without TPMT enzyme testing
🔴 NEVER prescribe NSAIDs in UC (recognised flare trigger)
🔴 NEVER colonoscope in suspected toxic megacolon
🔴 NEVER give live vaccines while on immunosuppressants
✅ Always prescribe Ca + vitamin D alongside steroids
✅ Always check allopurinol before azathioprine (major interaction)
| Monitoring | Frequency | Action threshold |
|---|---|---|
| TPMT enzyme | Before starting | Absent TPMT → do not use; Low TPMT → 50% dose; Normal → standard 2–2.5mg/kg |
| FBC + LFTs | Fortnightly ×8 weeks, then monthly ×3, then 3-monthly | WBC <3.5 or neutrophils <1.5 → hold + urgent GI; ALT >3× ULN → hold + GI |
| Allopurinol interaction | Check before every prescription | Concurrent allopurinol → reduce azathioprine by 75% — life-threatening myelosuppression if missed |
| Skin surveillance | Annual skin check | Increased melanoma and NMSC risk; SPF50+ sun protection; dermatology referral for suspicious lesions |
| Mesalazine nephrotoxicity | 3-monthly initially; annually thereafter | eGFR fall >25% → hold mesalazine; GI + nephrology advice |